大蒜素治疗急性脑梗死临床研究.doc

A Clinical Study of Garlicin in Treating Acute Cerebral Infarction*
Shi Zaixiang (史载祥), Zhang Jiuliang (张久亮), Mao Jiansheng (毛建生)
Zhang Tiezhong (张铁忠), Li Haicong (李海聪), Du Jinxing (杜金行)
Huang Li (黄力) and Cao Qifu (曹启富)
The China-Japan Friendship Hospital, Beijing (100029)
Zi Bohai (自伯海)**,Shi Yiting (石义亭)**,Liu Aihua (刘爱华)***,Wei Qing (魏青)***
ABSTRACT Objective: To evaluate the effect of garlicin in treating acute cerebral infarction. Methods: One hundred and one patients of acute cerebral infarction diagnosed by CT were treated with garlicin (garlicin group) pared with another group of 53 patients treated with ligustrazine (control group). The neurologic deficiency score and neurologic function score were used for evaluation of : The effective rates of garlicin and ligustrazine were % and % respectively. The improvement scores of neurologic function were ± and ± respectively. The difference between the two groups was significant. Before treatment the serum level of MDA in the garlicin group was ± nmol/ml, and it decreased to ± nmol/ml after treatment, the change being more significant than that of the control group (from ± nmol/ml to ± nmol/ml). The rheological parameters and cerebral blood flow were also improved after garlicin treatment. Conclusion: Garlicin could increase the perfusion flow